18^th Annual Pharma Middle East Congress November 05-07, 2018 Radisson Blu Hotel, Yas Island, Abu Dhabi, UAE

Biography:

Dr Ibrahim Elsayed is an associate professor and chair of Pharmaceutical Sciences department at Gulf Medical University, Ajman UAE. He did his PhD in Pharmaceutics and Industrial Pharmacy from Cairo University in 2011 and graduation diploma in Health-Professions Education from Gulf Medical University in 2015. He has experience in teaching almost all pharmaceutics courses including dosage forms, biopharmaceutics, pharmacokinetics, reaction kinetics, industrial pharmacy, quality control and assurance. As an administrator, he did preparation of the self-study report for CAA accreditation and ACPE certification, Developing integrated pharmacy curricula., Preparation of the college strategic plan 2017-2022, Participation in employment, quality assurance, assessment and curriculum committees, Developing and monitoring course and instructor online evaluation forms, Preparation and revision of course syllabi and files, Creating lectures and exams timetables using advanced software, Establishing nanotechnology research and IV skills labs.

Abstract:

The seminar gives an introduction to Design Expert^® software to enable the audience to start using it. This software is a professional statistical tool used to create the experimental design, study the effects of different factors with the least possible number of trials and optimize the designed process through simultaneous selection of the desired level of each independent variable. Different statistical plans can be utilized as full factorial, response surface and mixture designs. The response surface is the most commonly used design in pharmaceutical research and it includes different sub-designs; e.g. central composite and Box-Behnken. Before starting the experimental part, the studied factors and traced responses are loaded into the Design Expert^® software to determine the number and compositions/conditions of the experimental trials. After finishing the experimental work, the obtained data are fed into the software to assign different desirability values to the conducted experimental trials. Consequently, we can select the optimum trial having the maximum desirability value to be subjected to further investigations.

Biography:

Syed Muzammil Afzal has completed his PhD from Kakatiya University, Warangal, India. He has more than a decade of teaching and research experience. His research interest includes the development of lipid nanoemulsions for a tumour & brain targeting, development & evaluation of novel drug delivery systems like Nanoemulsions, Nanoparticles, etc. He has published 12 papers in reputed journals and presented research findings at various national & International conferences. He is the reviewer for the Journal of drug targeting. He is a recipient of UGC, AICTE fellowships awarded by the Government of India. He is the CPCSEA Nominee selected by Ministry of an environment, Government of India. Presently, he is Associate Prof & Head of Pharmaceutics in Sri Shivani College of Pharmacy, India.

Abstract:

The aim was to develop tumour-targeted docetaxel lipid nanoemulsions with four strategies for improving the antitumor activity and compare their targeting efficiencies. The O/W lipid nanoemulsions (L), were prepared by homogenization followed by ultrasonication process. The size of globules and zeta potential were measured by Malvern Zetasizer. The drug content and entrapment efficiencies for the lines were determined by HPLC. The in-vitro cytotoxic studies of the delivery systems were performed on MCF-7 and HeLa cells. The IC50 values of targeted lines on both the cell lines were statistically significant (P<0.05) when compared to DS (Docetaxel solution) & DLNE (Docetaxel LNE). The in-vivo antitumor activity was tested on solid tumours induced in C57BL/6 mice. This study revealed that the percentage a tumour inhibition, when compared with the control (untreated), were found to be 55.62%, 70.80%, 89.31%, 54.25%, 80.0% and 84.66% for the DLNE, PLNE, FLNE,SALNE, ALNE and TFLNE formulations respectively. Further, in-vivo distribution studies were carried out in breast cancer, MDA-MB231 induced tumours in Balb/c mice. The LNEs were loaded with fluorescent DiD oil and the distribution in different organs after 6hrs was tracked by small animal in-vivo imaging system. When compared with the DLNE the average radiance values at the tumour site for the formulations PLNE, FLNE, SALNE, TFLNE and ALNE were found to be increased by 2.31, 4.81, 1.35, 3.54 and 3.04 folds respectively. The tumour targeting efficiency was found to be in the order FLNE> TFLNE>ALNE> PLNE>SALNE>DLNE by an imaging study. 

Biography:

Anteneh Assefa (B.Pharm, MSc), is a Lecturer of Pharmaceutics & Pharmacology, Wachemo University. He is the expertise in pharmaceutical dosage form design and drug supply chain management. He has due experience of delivering pharmaceutical service to patients at hospitals, forecasting, quantifying and distribution of pharmaceuticals and medical equipment to health facilities and delivering/ instructing and​ training students and health care providers. Currently,  he is offering various pharmaceutics and pharmacology courses to the pharmacy and other medical students; besides he is working on various basic and applied researchers. He is serving as Head of School of Pharmacy. 

Abstract:

Starch is the most commonly used pharmaceutical disintegrant in tablet formulations. The aim of the present study was to assess the disintegrant property of Ethiopian potato (Plectranthus edulis) starch in comparison to Irish potato starch and its optimization in paracetamol tablets formulations - prepared by wet granulation method. Tablet properties such as crushing strength, friability, disintegration time, and dissolution rate of the tablets were studied for both comparison and optimization studies. The results of the comparative study showed that the properties of paracetamol tablets formulated with both starches as disintegrants were affected by their concentration and the compression force (CF); and P. edulis starch exhibited a favourably comparable disintegrant property with Irish potato starch in paracetamol tablet formulations. The study also showed that the CF and disintegrant concentration had significantly affected the response variables (i.e., the crushing strength, friability and disintegration time); hence, these factors were further optimized using central composite statistical design. The optimal conditions were obtained at a CF of 14.40 KN and disintegrant concentration of 5.96%. Under these conditions, the crushing strength, friability and disintegration time were 101.8 KN, 0.3% and 1.34 min, respectively. These values closely matched with the predicted values of the responses at the aforementioned levels of the factors. Thus, the results of this study indicated that Ethiopian potato (P. edulis) can be used as an alternative source of starch for its application as a disintegrant in the tablet formulations

Biography:

Rashida Muhammad Umar is an assistant professor at Istanbul Medipol University, Istanbul. She earned her first degree in pharmacy from Hacettepe University Ankara in 2011 and her PhD in clinical pharmacy from Marmara University Istanbul in 2017. She is a dedicated lecturer focused on the improvement of pharmacy education and the application of clinical pharmacy in the health care system.

Abstract:

Cancer is one of the leading causes of death globally with increasing prevalence.  Treatment in cancer patients is complicated as it obliges the use of drugs with narrow therapeutic window and high toxicity to treat cancer, in addition to supportive care medications to treat disease-related and therapy complications and also comorbidities. As such cancer patients are prone to drug-related problems. Comprehensive medication management (CMM) is defined by the American College of Clinical Pharmacy as “the standard of care that ensures each patient's medication (including non-prescription drugs, traditional and alternative therapies and supplements) are individually assessed to determine that each medication is appropriate for the patient, effective for the medical condition, safe given to comorbidities and other medications are taken, and able to be taken by the patient as intended”. 

Biography:

Dr Minoo Shahidi is an academic member of the Hematology group at the Iran University of Medical Sciences (IUMS). In 2010, she achieved her PhD from the University of Surrey, UK. During her several year careers as a lecturer at IUMS, she published a number of books and papers. In addition, she conducted some projects and received certificates of the invention. She also dedicates herself in providing help to her postgraduate students as well as to professionals and offers tutorials for them to pass their thesis via her projects in the field of novel treatment approaches for leukaemia and hemostasis.

Abstract:

Statement of the Problem: Since human umbilical vein endothelial cells (HUVEC) can be simply collected, developing of hematopoietic progenitor cells from these cells may improve hematopoietic cell engraftment for irregular cases with limitations for receiving compatible blood components. Regenerative functions of Silymarin, a mixture of polyphenolic flavonoids derived from milk thistle, have been reported previously. Accordingly, there are some reports of Silymarin effect in regeneration and treatment of skin disorders, but no effect of this polyphenolic flavonoid on hematopoietic cells has been reported so far. The purpose of this study was to investigate the direct effect of Silymarin on conversion of HUVEC to hematopoietic cells. The effect of Silymarin on all the main hematopoietic lineage markers in HUVEC was investigated after 24h by flow cytometry and immunocytochemistry. Treatment of endothelial cells with Silymarin after 24h significantly increased the number of the cells expressing hematopoietic progenitor markers. However, no significant expression of the lineage-specific markers was found during 24h. Taken together, our in vitro findings revealed the potential of Silymarin to switch human 

Biography:

Dr Anmar AL-TAIE is a teaching faculty member in clinical pharmacy discipline both practical and theoretical academic platforms at pharmacy department-Osol Aldeen University College. He finished his PhD study in Clinical at Marmara University- Faculty of Pharmacy- Clinical Pharmacy Department. He also finished his MSc in clinical pharmacy and BSc in pharmacy at Baghdad University –College of Pharmacy. He conducts many studies in fields of clinical pharmacy practice that were published in reputed journals and international conferences and is as an active reviewer in a number of reputed journals (such as the International Journal of Clinical Pharmacy and Supportive Care in Cancer). He has several participations in local and global activities regarding clinical pharmacy discipline.

Abstract:

Diabetes mellitus (DM) and cancer are considered as severe complicated conditions that can pose an additional significant clinical challenge and have a tremendous impact on health. The vast majority of DM cases are type 2, which are associated largely with older overweight age patients and those with family history. Studies showed that comorbid medical conditions such as DM affect 8-18% of all cancer patients. Such patients have fewer reserves in their body to fight against the various complications, such as infections. Moreover, chemotherapy could exacerbate pre-existing diabetes and induce hyperglycaemia especially in patients who already had a propensity toward developing the disease while their side effects can make it more difficult to keep blood glucose levels in control. Furthermore, stress accompanied the disease itself and the use of corticosteroids during chemotherapy, as part of the antiemetic regimes or to prevent allergic reactions caused by some chemotherapy drugs may be continued after chemotherapy for a certain period of time. Steroids can raise blood glucose levels pretty markedly and a few days of hyperglycaemia contribute to the uncontrolled DM in patients undergoing chemotherapy. In this regard, diabetes treatments need to be adjusted, especially around the time that the steroids are given. 

Biography:

Kriti Ray, M. Sc. She is pursuing her Ph.D. under the Deakin India Research Initiative (DIRI) program initiated between Reliance Institute of Life Sciences, India and Deakin University, Australia. Her study focuses on developing reporter assays for antibody-based therapeutics. She has also worked with siRNA-based therapeutics against cancer and dengue.

Abstract:

Aim of the study: Biopharmaceuticals will comprise around 27% of the global pharmaceutical market in the near future, and monoclonal antibodies (mAbs) are predicted to take the major share due to their favourable drug properties such as specificity, high efficacy and fewer side-effects. Hence, testing mAbs for their efficacy and stability before batch release is an important aspect of the mAb development and manufacturing program. Here, we aim to design and validate an in-vitro reporter gene-based assay for the evaluation of anti-IL6/IL6R and anti-EGFR mAbs with immense therapeutic potential and to make the stability testing procedure more robust, precise and rapid in comparison to existing assays.

Biography:

Anteneh Assefa (B.Pharm, MSc), is a Lecturer of Pharmaceutics & Pharmacology, Wachemo University. He is the expertise of pharmaceutical dosage form design and drug supply chain management. He has due experience of delivering pharmaceutical service to patients at hospitals, forecasting, quantifying and distribution of pharmaceuticals and medical equipment to health facilities and delivering/ instructing and training students and health care providers. Currently, he is offering various pharmaceutics and pharmacology courses to the pharmacy and other medical students; besides he is working on various basic and applied researchers. He is serving as Head of School of Pharmacy. 

Abstract:

Starch is the most commonly used pharmaceutical disintegrant in tablet formulations. The aim of the present study was to assess the disintegrant property of Ethiopian potato (Plectranthus edulis) starch in comparison to Irish potato starch and its optimization in paracetamol tablets formulations - prepared by wet granulation method. Tablet properties such as crushing strength, friability, disintegration time, and dissolution rate of the tablets were studied for both comparison and optimization studies. The results of comparative study showed that the properties of paracetamol tablets formulated with both starches as disintegrants were affected by their concentration and the compression force (CF); and P. edulis starch exhibited a favorably comparable disintegrant property with Irish potato starch in paracetamol tablet formulations. The study also showed that the CF and disintegrant concentration had significantly affected the response variables (i.e., the crushing strength, friability and disintegration time); hence, these factors were further optimized using central composite statistical design.

Biography:

Maha AlMolaiki was graduated from King Saud University(KSU) with Pharm.D. degree, an employee in King Abdulaziz Medical City-Central Region(KAMC-CR) since 2014, who assists in patient care, both in outpatient and inpatient settings, joined the pharmacy residency program in 2016, currently pharmacy resident. Had two publications.

Abstract:

Aim: to assess the likelihood of developing new-onset ischemic stroke among patients who were using PPIs for 6 months or more versus patients who were not using PPIs. 

Background: Stroke is a rapid loss of brain function due to disruption of blood supply to the brain and a major cause of mortality and morbidity worldwide. In Saudi Arabia, the incidence of ischemic strokes is 69%. The established risk factors are hypertension, diabetes mellitus, smoking, dyslipidemia. Proton pump inhibitors (PPIs) one of the world’s most frequently prescribed medications contributed to many adverse effects. In 2016, a retrospective study found a significant increase in the risk of new onset ischemic stroke in the PPIs users. In 2018, a prospective cohort study found no association. 

Biography:

Joseph Miller is chair of pharmacology at American University of the Caribbean School of Medicine. He has nearly one hundred publications for the most part in the area of neuropharmacology with a particular focus on dopaminergic and serotonergic effects on sleep and circadian rhythms. For many years he has been involved with NASA examining the effects of microgravity on neurotransmitter receptors and examining the possibility of bacterial life on Mars.

Abstract:

The phenomenology of drug addiction seems to vary greatly between depressant drugs of abuse and stimulant drugs of abuse. For instance, the effects of withdrawal seem to be more deleterious for depressant drugs while withdrawal from stimulant drugs seems more likely to generate craving. The purpose of this study is to examine the anatomy and physiology of the nigrostriatal and mesocortical projections with a view to incorporate the major theories of drug addiction. Furthermore, the wiring diagrams of these projections suggest specific anatomical loci whose dysfunction may produce a proclivity toward the development of dependency and addiction in a sub-population of the human race.  Methodology & Theoretical Orientation: We have reviewed a large percentage of the literature on drug dependency with a particular focus on available theoretical models of drug abuse and addiction. We have integrated that material into what we believe to be a comprehensive model of drug addiction. Findings: We believe the most likely candidates responsible for drug addiction proclivity are dopamine receptor down-regulation in a number of loci and/or dysfunction in the dopamine transporter. Conclusion & Significance: If the mechanisms implicated here are critical to the development of drug addiction those mechanisms could be the target of next-generation pharmacotherapy for drug addiction.

Biography:

Twenty years from cumulative experiences through the pharmaceutical industry starting from basic job duties and moved into extremely detailed and challenging positions; with different geographical levels from country scale to LEVANT & now the Middle East & North Africa responsibilities.  Generations of evaluation: measurement, description and judgment. It allows for value-pluralism. This approach is responsive to all stakeholders and has a different way of focusing. My current responsibilities as Country –Head for Iraq and Kurdistan territory involve working to manage operations, develop business and increase profitability for Hikma Pharmaceutical group

Abstract:

For many years, generic versions of those medicinal products have been on the market that contains chemically synthesized active ingredients. These generics are essentially similar to the innovator’s product and contain the same active ingredient in the same quantity. Such generic products may be approved after the patent for the innovator’s product has expired. Neither efficacy nor safety studies are required for the approval of a generic drug; it is sufficient to refer to the documentation provided by the innovator. With more number of new mABs, coupled with the expiry of the patents and more affordability is expected to generate the overall sales of nearly US$125 billion in the next 4-5 years. Monoclonal antibodies (mAbs) contribute almost 60% of market revenue among the top ten bestseller drugs worldwide. The growth of the biosimilar market is driven by the numbers of patents getting expired in the coming years, regulations and guidelines for the manufacturing of different class of biosimilars and potential demand for these products. Although, a few new mAbs that have gained regulatory approval in the last few years, it is expected to have 70 mAbs product in the global market by 2020. The market for mAbs is expected to grow in near future due to, patent expiry of few blockbuster drugs and new products in the pipeline. European and US market is wide open due to the patent expiry which influences the Asian drug makers. It is expected that the emerging Biosimilars market, especially in China, India, Brazil and MENA will record high growth rate driven by cost-effectiveness of Biosimilars and the growing awareness supported by growing healthcare infrastructure in these countries.

Biography:

Prakash.M.M.S Kinthada, is a Professor in the Department of Chemistry at Sri Vidyanikethan Engineering college, Jawahar Lal Technological University, Anantapur, A. Rangam Peta, Tirupathi, India. Earlier I was an Associate Professor of Chemistry, GIT, Gitam University, Visakhapatnam, India. I have recently returned from the USA, where I was an NIH visiting fellow at Karmanos Cancer ReseaInstitutetee, Wayne State University School of medicine. Earlier I was a Royal Society Visiting Scientist in the inorganic chemistry laboratories at the University of Oxford, UK, working on" Transition metal complexes as Anticancer Drugs". Earlier I was a visiting fellow at the Department of ChemicalEngineering and Applied Chemistry at Aston University, Birmingham. Prior to that, I was a Nehru Centenary British Council Fellow in the organometallic laboratories at the Imperial College of Science, Technology and Medicine, London, UK. Prior to that, I was a CSIR Research associate in the Organometallic laboratories, Department of chemistry, Indian Institute of Technology, New Delhi India. I have published all my research in high impact international journals and Presented paper in International Conferences including American Chemical society conferences. I have published 33 International publications and 31international conference presentations including American ChemicalSociety conferences.

Abstract:

The main aim of our extensive/preclinical Pharmaceutical development program is to investigate the use of these extremely novel small molecules-metal complexes/compounds of phytochemicals, flavonoids etc., which have very interesting structural features and properties and hence are excellent candidates as Anti-Cancer and Anti-HIV drugs. The main aim of our research is Design, Development and Synthesis of Transition Metal Complexes/ Organometallic Compounds that would certainly help to bring this force of nature from BENCH to BEDSIDE and enhance Cancer Killing with less toxic effects and would certainly lead to the initiation of clinical trials. Cancer is a dreadful disease and any practical solution in combating this disease is of paramount importance to public health. Cancer patients have burdened by drug-induced toxic side effects, and no turned to seek help from the complementary and alternative medicine hoping for a better cure. Research on Platinum-based drugs and Non-Platinum based drugs is a Multi-Million Dollar Industry in the USA and there is every need to produce safe drugs for the cure of this monstrous disease. Flavonoids have a long history of use in traditional medicines in many cultures.